Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
244
NCT01940133
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2014
Completion: Dec 31, 2015
NCT02249429
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
Phase: Phase 2
Start: May 31, 2015
Completion: Sep 11, 2018
NCT02850744
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
Start: Jul 31, 2015
Completion: Nov 30, 2017
NCT02669511
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Start: Nov 12, 2015
Completion: Jan 12, 2018
NCT02723877
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
Phase: Phase 1/2
Start: Mar 28, 2016
Completion: Oct 3, 2018
NCT03127020
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
Start: Jun 30, 2016
Completion: Not specified
NCT03120000
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Start: Dec 31, 2017
Completion: Dec 31, 2019
NCT02483858
Study of Oral PQR309 in Patients With Advanced Solid Tumors
Start: Mar 21, 2019
Completion: Mar 21, 2019
NCT04441099
NBE-002 in Patients With Advanced Solid Tumors
Start: Jun 19, 2020
Completion: Aug 14, 2023